Dr Richard Mollard has over 25 years of national and international experience in biomedical technical diligence, business development and research design and translation.

He has held drug R&D positions in France, the US and Australia working with: Bristol Myers Squibb/ IGBMC/ University Louis Pasteur, Eli Lilly & Co/University of Michigan and Monash University. He has also held several international executive positions including CSO in listed and private biotech/pharma companies and has extensive experience in drug CMC, reformulation, regulatory affairs and commercialisation.

Richard has assisted in raising over AUD 120 million through placements, rights issues, government grants and philanthropic charities and organisations. He is also the author of 38 peer- reviewed and invited scientific journal publications and is currently an Honorary Fellow with the Department of Veterinary Sciences and Agriculture at the University of Melbourne.

David graduated from The University of Sydney, after graduation he was appointed as a clinical instructor at The University of Sydney and completed  PhD programme in the Faculty of Medicine looking at various aspects of the pathophysiology of diabetes mellitus.

Later appointed as a member of faculty in small animal medicine at The University of Sydney rising to become Hospital Director of The University Veterinary Centre.

In 2001 David was appointed Chair of Small Animal Studies at the Royal Veterinary College and head of the newly formed Department of Veterinary Clinical Sciences. The department grew to be one of the largest and successful clinical departments in the world with substantial research grant funding. David maintains an interest in endocrinology. His current research interests include insulin resistance states in diabetes mellitus and the use of ‘big data’ from general practice for managing animal health and welfare.

David is the author of over 150 scientific articles, numerous book chapters, is editor of the highly successful textbook Small Animal Clinical Pharmacology.

ARKAY Therapeutics LLC are a group of globally renowned Professors, Scientists, Practising and Academic Endocrinologists and Regulatory Affairs specialists with extensive clinical trial experience in both big pharmaceutical and private companies. ARKAY's team are based across the United States of America. 

John is an independent consultant and a sessional university lecturer specializing in investments, capital budgeting techniques and corporate finance in general, including international financial management. He has advised clients including Myopharm, Aurora Energy, ActewAGL, the APA Group, Epic Energy and the Victorian Government. Until 2008 John held middle and senior management positions in ExxonMobil over a 21-year period including 3 years as economics lead in natural gas, developing business cases & conducting modelling to do with large upstream investments & divestments. John's downstream experience is also extensive and includes fuels & lubricants sales & marketing, high-value procurement, logistics & distribution and change management, including company restructures and large compliance programs.

Specialty areas: Capital Investment analysis, financial & other business modelling including valuations of assets and companies.